ASX & MEDIA RELEASE
15 NOVEMBER, 2012

NOVOGEN CAPITAL REDUCTION: INDICATIVE TIMETABLE

As previously announced, Novogen's shareholders approved an equal capital reduction, to be effected by Novogen making a distribution to all of its shareholders of approximately six shares of common stock in MEI Pharma, Inc. for every 35 Novogen ordinary shares held by them on the record date (**Capital Reduction**).

Novogen confirms that in accordance with ASX regulatory requirements for a capital reduction, the indicative timetable for the Capital Reduction remains as set out in the explanatory statement for the Annual General Meeting dated 11 October 2012.

Event	Date
Start of trading of the Novogen Limited shares on an 'ex return of capital basis'	14 November 2012
Record Date	20 November 2012
Distribution/Despatch Date	27 November 2012

About Novogen Limited

Novogen Limited is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, MEI Pharma, Inc. More information on the Novogen group of companies can be found at www.novogen.com.

ISSUED FOR	**:**	**NOVOGEN LIMITED**
LISTINGS	**:**	**ASX (CODE NRT), NASDAQ (CODE NVGN).**
FOR FURTHER INFORMATION	**:**	**WILLIAM D RUECKERT, CHAIRMAN, NOVOGEN**
LIMITED		**TEL +612 9878 0088**
ISSUED BY	**:**	**WESTBROOK COMMUNICATIONS**
CONTACT	**:**	**IAN WESTBROOK TEL (02) 9231 0922**